


BTS/NICE/SIGN 2024 Guidelines (NG245) for the pharmacological management of asthma in people aged 12 years and older¹



Uncontrolled asthma: Any exacerbation requiring oral corticosteroids or frequent regular symptoms (such as using reliever inhaler 3 or more days a week or nighttime waking 1 or more times a week)¹

Adapted from BTS/NICE/SIGN 2024 Guideline - please see full guideline for all information

This guideline does not recommend specific products – Fobumix Easyhaler® is an option for your patients in MART and AIR. Take into account and try to address the possible reasons for uncontrolled asthma before starting or adjusting medicines.

AIR, anti-inflammatory reliever
ICS, inhaled corticosteroid;
LABA, long-acting beta2 agonist;
LAMA, long-acting muscarinic receptor antagonist; **LTRA**, leukotriene receptor antagonist; **MART**, maintenance and reliever therapy (using ICS/formoterol combination inhalers); **SABA**, short-acting beta2 agonist.

Existing diagnosis of asthma on the treatment pathway recommended by previous NICE and BTS/SIGN guidelines¹

Patients on SABA Only

Offer **low-dose AIR therapy with ICS/Formoterol** (to be taken as needed)



Fobumix Easyhaler® 160/4.5

Fobumix Easyhaler®
160/4.5:
60 dose pack: £10.75
120 dose pack: £21.50

If uncontrolled asthma on **SABA** as well as either:

- Low-dose **ICS**
- Low-dose **ICS/LABA**
- Low-dose **ICS plus LTRA**
- Low-dose **ICS/LABA plus LTRA**

Consider

Low-dose MART with Fobumix Easyhaler®



Fobumix Easyhaler® 80/4.5
Fobumix Easyhaler® 160/4.5

Fobumix Easyhaler®
80/4.5:
120 dose pack: £21.50
Fobumix Easyhaler®
160/4.5:
60 dose pack: £10.75
120 dose pack: £21.50

If uncontrolled asthma on **SABA** as well as either:

- Moderate dose **ICS**
- Moderate dose **ICS/LABA**
- Moderate dose **ICS plus LTRA and/or LAMA**
- Moderate dose **ICS/LABA plus LTRA and/or LAMA**

Consider

Moderate dose MART with Fobumix Easyhaler®



Fobumix Easyhaler® 160/4.5

Fobumix Easyhaler®
160/4.5
60 dose pack: £10.75
120 dose pack: £21.50

If asthma is uncontrolled on **high-dose ICS**

Refer people to a specialist in asthma care

Fobumix Easyhaler® Indication:

Asthma: Regular treatment of asthma where the use of a combination (inhaled corticosteroid and long-acting beta-2-adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting beta-2-adrenoceptor agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting beta-2-adrenoceptor agonists.

Fobumix Easyhaler® 80/4.5mcg: indicated for maintenance therapy in patients ≥6 years of age, and MART in patients ≥12 years of age.

Fobumix Easyhaler® 160/4.5mcg: indicated for reliever therapy (as-needed, AIR) in mild asthma, maintenance therapy and MART in patients ≥12 years of age.

Fobumix Easyhaler® 320/9mcg: indicated for maintenance therapy only in patients ≥12 years of age.

Note: Fobumix Easyhaler® 80/4.5mcg is not appropriate in patients with severe asthma.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300

References

1. BTS/NICE/SIGN Guidelines 2024. Asthma: diagnosis, monitoring and chronic asthma management. Revised November 2024. <https://www.nice.org.uk/guidance/ng245>. Accessed: August 2025.

Uncontrolled asthma: Any exacerbation requiring oral corticosteroids or frequent regular symptoms (such as using reliever inhaler 3 or more days a week or nighttime waking 1 or more times a week)¹

Adapted from BTS/NICE/SIGN 2024 Guideline - please see full guideline for all information

This guideline does not recommend specific products – Fobumix Easyhaler® is an option for your patients in MART and AIR.
Take into account and try to address the possible reasons for uncontrolled asthma before starting or adjusting medicines.

CLICK HERE for Fobumix Easyhaler® Prescribing Information

Scan here for
Fobumix Easyhaler®
prescribing information

